Welcome to our dedicated page for So-Young Intl news (Ticker: SY), a resource for investors and traders seeking the latest updates and insights on So-Young Intl stock.
So-Young International Inc. (SY) operates China's leading digital platform for medical aesthetics discovery and reservations. This news hub provides investors and industry observers with essential updates about the company's operational developments, strategic partnerships, and market position within the evolving healthcare services sector.
Track official press releases covering quarterly earnings, technology initiatives, and provider network expansions alongside curated analysis of SY's unique vertical integration model. Our repository includes updates on:
• Financial disclosures including SEC filings and earnings call details
• Strategic collaborations with medical equipment manufacturers and clinics
• Platform enhancements to its social community and booking systems
• Regulatory developments affecting China's medical aesthetics sector
Bookmark this page for streamlined access to verified information about SY's dual role as both digital content curator and physical service facilitator in the $10B+ Chinese medical beauty market. Check regularly for updates on how the company maintains its competitive edge through vetted provider networks and data-driven consumer insights.
So-Young (Nasdaq: SY) reported unaudited Q3 2025 results on November 17, 2025. Total revenue was RMB386.7 million (US$54.3M), up 4.0% year‑over‑year. Aesthetic treatment services revenue rose to RMB183.6 million (US$25.8M), a 304.6% increase from Q3 2024 and above guidance.
The company operated 39 branded aesthetic centers at quarter end, with over 89,800 verified treatment visits and 194,700 treatments in the quarter. Active users exceeded 130,000. 20 centers reached profitability and 29 centers produced positive quarterly operating cash flow.
Q3 net loss attributable to So-Young was RMB64.3 million (US$9.0M); non-GAAP net loss was RMB61.6 million (US$8.7M). Cash and equivalents were RMB942.8 million. Guidance for Q4 2025 aesthetic treatment revenue is RMB216.0–226.0 million (165.8%–178.1% YoY increase).
So-Young (NASDAQ: SY) will report third quarter 2025 financial results for the period ended September 30, 2025 before U.S. markets open on November 17, 2025.
Management will host an earnings conference call on November 17, 2025 at 7:00 AM ET (8:00 PM Beijing/Hong Kong time). Telephone replay will be available from two hours after the call through 23:59 ET on November 24, 2025. A live and archived webcast will be available at http://ir.soyoung.com.
So-Young International Inc. (Nasdaq: SY), China's leading aesthetic treatment platform, reported Q2 2025 financial results showing mixed performance. Total revenues decreased 7.0% to RMB378.7 million (US$52.9 million) compared to Q2 2024. The company reported a net loss of RMB36.0 million (US$5.0 million), contrasting with a net income of RMB18.9 million in Q2 2024.
Notable highlights include aesthetic treatment services revenues surging 426.1% to RMB144.4 million, becoming the largest revenue contributor for the first time. The company now operates 29 branded aesthetic centers across nine major Chinese cities, with 25 centers achieving positive monthly operating cash flow. The number of verified treatment visits reached 67,400, with over 154,500 verified paid aesthetic treatments performed.
For Q3 2025, So-Young expects aesthetic treatment services revenues between RMB150.0-170.0 million, representing 230.5-274.6% year-over-year growth.
So-Young International Inc. (NASDAQ: SY), China's leading aesthetic treatment platform, reported Q2 2025 financial results with total revenues of RMB378.7 million (US$52.9 million), down 7.0% year-over-year. The company's aesthetic treatment services revenue surged 426.1% to RMB144.4 million, becoming the largest revenue contributor for the first time.
The company now operates 29 branded aesthetic centers across 9 major Chinese cities, with 25 centers achieving positive monthly operating cash flow. Key operational metrics showed significant growth, with verified treatment visits reaching 67,400 and active users exceeding 100,400. However, So-Young reported a net loss of RMB36.0 million, compared to a net income of RMB18.9 million in Q2 2024.
For Q3 2025, So-Young expects aesthetic treatment services revenues between RMB150.0-170.0 million, representing 230.5-274.6% year-over-year growth.
[ "Aesthetic treatment services revenue grew 426.1% year-over-year to RMB144.4 million", "25 out of 29 branded aesthetic centers achieved positive monthly operating cash flow", "Verified treatment visits increased significantly to 67,400 from 14,000 year-over-year", "Active users grew to 100,400 from 16,000 in the corresponding period", "Strong Q3 2025 guidance projecting 230.5-274.6% growth in aesthetic treatment services" ]So-Young International (NASDAQ: SY), China's leading aesthetic treatment platform, will release its Q2 2025 financial results on August 15, 2025, before U.S. markets open.
The company will host an earnings conference call on August 15, 2025, at 7:30 AM ET (7:30 PM Beijing/Hong Kong Time). A telephone replay will be available until August 22, 2025, and investors can also access the live and archived webcast through the company's investor relations website.
So-Young International (Nasdaq: SY), China's leading aesthetic treatment platform, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received confirmation from Nasdaq on July 2, 2025, after maintaining a closing bid price of $1.00 or higher for its American depositary shares (ADSs) for 10 consecutive business days from June 17 to July 1, 2025.
This development resolves the compliance issue that began on August 28, 2024, when So-Young was initially notified of non-compliance. The company had received two compliance periods: an initial 180-day period until February 24, 2025, followed by an extension until August 25, 2025. With this requirement now met, Nasdaq has closed the matter.
So-Young International Inc. (NASDAQ: SY), China's leading aesthetic treatment platform, has scheduled its first quarter 2025 financial results announcement for May 16, 2025, before U.S. markets open. The company will host an earnings conference call on the same day at 7:30 AM U.S. Eastern Time (7:30 PM Beijing/Hong Kong Time). A telephone replay will be available until March 23, 2025, and interested parties can also access a live and archived webcast of the conference call through the company's investor relations website.